Labeled for this condition
Medicines for stroke prevention
10 medicines have an FDA label indicated for stroke prevention; 9 are listed from generic labelers and 0 have a presentation in shortage now (FDA files, October 8, 2026).
Which medicines are labeled for stroke prevention?
Each label names the condition in its indications; the record shows the label's words. A list of labeled medicines is not a treatment plan.
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Rosuvastatin | Crestor | 45 labelers | $0.0692 per tablet 40 mg tablet | No | No current entry | 13 |
| Losartan | Cozaar, Arbli | 43 labelers | $0.0327 per tablet 50 mg tablet | Yes | No current entry | 77 |
| Hydrochlorothiazide and losartan | Hyzaar | 29 labelers | $0.0762 per tablet 100-12.5 mg tablet | Yes | No current entry | 29 |
| Amlodipine and atorvastatin | Caduet | 6 labelers | $1.34 per unit 10-40 mg | No | No current entry | 13 |
| Ticagrelor | Brilinta | 28 labelers | $0.253 per tablet 90 mg tablet | Yes | No current entry | 2 |
| Dabigatran | Pradaxa | 16 labelers | $0.795 per capsule 150 mg capsule | Yes | No current entry | 9 |
| Rivaroxaban | Xarelto | 20 labelers | $0.650 per tablet 2.5 mg tablet | Yes | A presentation being discontinued | 1 |
| Apixaban | Eliquis | 2 labelers | $5.52 per tablet 5 mg tablet | Yes | No current entry | 0 |
| Aspirin and dipyridamole | none listed | 9 labelers | $0.559 per unit 25-200 mg | No | No current entry | 2 |
| Edoxaban | Savaysa | none listed | $15.51 per tablet 60 mg tablet | Yes | No current entry | 0 |
Source: FDA drug labels (indications) via openFDA; NDC Directory; CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)
What do pharmacies pay?
Each medicine's most widely listed form, per unit, in the NADAC survey: what pharmacies paid, not what a patient pays; strengths differ, so compare like with like.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price